

1 **Altered Relaxation Times in Magnetic Resonance Imaging**

2 **Indicate Bronchopulmonary Dysplasia: Supplementary Material**

3

4 **Kai Förster, MD^{1,2§}, Birgit Ertl-Wagner MD^{3§}, Harald Ehrhardt MD⁴, Hannah Busen⁵,**
5 **Steffen Sass PhD⁵, Andreas Pomschar MD³, Lutz Nährlich MD⁴, Andreas Schulze MD¹,**
6 **Andreas W. Flemmer MD¹, Christoph Hübener MD⁶, Oliver Eickelberg MD², Fabian J.**
7 **Theis PhD^{5,7}, Olaf Dietrich PhD³, Anne Hilgendorff MD^{1,2}**

8

9 **S1 – S4 Patients and Methods**

10 **S1 Study population**

11 Approval by the local Ethics Committee was obtained prior to the initiation of the study
12 and parents provided written informed parental consent for all study infants (Munich
13 #195-07; Giessen #135/12). Study registration was performed at the German Registry
14 for Clinical Studies (DRKS00004600).

15 Preterm infants with or without later development of BPD and a gestational age (GA)
16 of ≤ 32 weeks born at the Perinatal Center of the Ludwig-Maximilians-University,
17 Campus Grosshadern (exploration cohort, n=40) were prospectively included in the
18 study. Imaging markers established in this cohort were then confirmed in a second,
19 independent cohort recruited at the Perinatal Center of the Justus-Liebig-University,
20 Giessen (confirmation cohort, n=21); see Table S1 for patient characteristics.

21 Exclusion criteria were severe congenital malformations (e.g. hypoplastic left-heart
22 syndrome, severe hypoplasia of the lungs or congenital diaphragmatic hernia),
23 chromosomal abnormalities (e.g. trisomy 13 or 18), inborn errors of metabolism, and
24 decision for palliative therapy directly after birth.

25 The following definitions were applied: BPD was defined according to Jobe and
26 Bancalari ¹ and graded as follows: mild (oxygen supplementation at 28 days

27 postnatally), moderate (need for < 30% oxygen at 36 weeks PMA or discharge,
28 whichever comes first), or severe (need for \geq 30% oxygen and/or ventilator support,
29 i.e. positive pressure ventilation (PPV) or nasal continuous positive airway pressure
30 (NCPAP)) at 36 weeks PMA or discharge, whichever comes first) BPD. Days with
31 ventilator support were recorded as endotracheal (invasive) mechanical ventilation,
32 nasal intermittent mandatory ventilation or nasal intermittent positive pressure
33 ventilation and/or nasal continuous positive airway pressure in days. A course of
34 antenatal corticosteroids was recorded as “complete” if two doses of betamethasone
35 were given >24 hours before birth with the last dose administered no later than 7 days
36 before birth. Chorioamnionitis was defined as the presence of inflammatory alterations
37 of the chorionic plate at histologic examination or signs of infection in both mother and
38 infant ². Intrauterine growth restriction was defined as birth weight below the 10th
39 percentile. Postnatally, diagnosis and severity of RDS (respiratory distress syndrome)
40 was scored on anterior-posterior (a.-p.) chest radiographs according to Couchard et al
41 ³ by a consensus panel of two experienced neonatologists and an experienced
42 radiologist with over 15 years of experience and blinded to the clinical information of
43 the patients. Systemic infections were diagnosed according to Sherman et al. ⁴ with
44 one or more clinical and laboratory signs of infection.

45 After discharged, patients were subject to home monitoring (getemed, Potsdam,
46 Germany) in case of frequent desaturations < 85% due to short apnoeic episodes or
47 periodic breathing requiring tactile stimulation or oxygen therapy. Home monitoring
48 was discontinued when breathing pattern normalized and apnoeic episodes did not
49 result in frequent oxygen saturation levels below 85%.

50 **S2 Pulmonary MR imaging**

51 **MR imaging protocol.** Pulmonary MR imaging measurements were performed at 36
52 weeks GA (35.4 weeks median GA) in non-sedated, spontaneously breathing infants
53 (fiO₂ 0.21) without administration of intravenous contrast and positioned in a supine
54 position while swaddled in a vacuum mattress after feeding (exploration cohort). A size-
55 adapted number of coil elements from a 32-channel spine array coil, an 18-channel
56 flexible body array coil and a 20-channel head-and-neck array coil was used in a 3-
57 Tesla whole-body MR scanner (Magnetom Skyra, Siemens Healthineers, Erlangen,
58 Germany). Hearing protection was performed by the use of MiniMuffs® (Neonatal
59 Noise Attenuators, Natus Medical Incorporated, Seattle, USA).

60 MR imaging measurements in the second cohort (confirmation cohort) followed the
61 same imaging protocol under light sedation with chloral hydrate (30-40 mg/kg
62 administered orally).

63 The protocol included pulse sequences for the assessment of morphology, volume,
64 and of quantitative relaxation parameters of the lung. In detail, the following pulse
65 sequences were used: i) T2-weighted single-shot fast-spin-echo (ssFSE) sequences
66 in coronal, axial, and sagittal orientation; spatial resolution 1.9×1.3×4.0 mm³, 20 slices
67 with a field of view (FOV) of 340×255 mm². The echo time (TE) was 57 ms; the
68 acquisitions were ECG-triggered with a minimum repetition time (TR) of 2 RR intervals;
69 2 signal averages were acquired. ECG triggering was performed to provide images
70 with lower level of motion artifacts around the heart. ii) Single-slice T2-mapping and
71 T1-mapping using ssFSE sequences (T2-mapping: TR = 2000 ms, TE = 26, 41, 61,
72 92 ms; T1-mapping: TR/TE = 3000 ms/26 ms, inversion time (TI) for slice-selective
73 inversion = 25, 150, 400, 800, 1600, 2600 ms and one acquisition without inversion
74 pulse) in coronal orientation (8 averages); spatial resolution: 2.3×2.3×20.0 mm³. For
75 T1 and T2 mapping, data from 8 acquisitions were averaged, thereby mitigating the

76 impact of respiratory or cardiac motion. FOV: 300×300 mm²; the 20 mm slab was
77 positioned in a representative central lung area capturing a substantial fraction of the
78 lungs in the anterior-posterior direction. The total acquisition time of the three T2-
79 weighted ssFSE sequences was approximately 5 minutes (depending on the heart rate
80 of the infant); the total acquisition time of the T2 and T1 mapping sequences was also
81 approximately 2 and 3 minutes, respectively.

82 **MR image analysis.** To ensure equal conditions for pulmonary imaging analysis, a
83 consensus panel ruled out significant atelectasis, air leaks or pleural effusion before
84 processing the respective images for further analysis. For T2- and T1-mapping
85 analysis, the lung was manually virtually segmented into four lung quadrants (upper
86 left, upper right, lower left, and lower right quadrants) using the software “Osirix MD”
87 (version 6.5) ⁵. T2 and T1 relaxation time values were calculated by non-linear
88 exponential fitting and evaluated for these four lung quadrants and for the entire lung
89 in order to consider regional differences and total lung changes. Free-breathing
90 average total lung volume was measured by manual lung segmentation in axial and
91 coronal acquisitions with the editor tool in the open-source software “3D Slicer” (version
92 4.3.1 r22599) ⁶; left and right main bronchi were excluded; further exclusion of airways
93 was limited by the small size of the segmented lungs. To reduce the influence of
94 measurement errors, the arithmetic means of the two volumes derived from axial and
95 coronal images was used (sagittal slices were not analysed due to the lack of
96 discernibility between tissues next to the mediastinum).

97 **S3 Infant Lung Function Testing (ILFT) in preterm infants at 36 weeks GA**

98 **ILFT protocol.** ILFT was performed at 36 weeks GA and standardized according to
99 the recommendations of the American Thoracic Society and European Respiratory
100 Society ^{7 8}. All infants were spontaneously breathing room air under light sedation

101 (chloral hydrate, 30-40 mg/kg; orally) and had been free of respiratory infection for
102 more than three weeks, presenting with normal blood pH values; optional inhalation
103 therapy was terminated three days prior to the study for the purpose of pulmonary
104 function testing. A highly standardized and optimized measurement setting minimized
105 intrinsic limitations of lung function measurements using body plethysmography in
106 infants with 2 kg bodyweight. Oxygen saturation levels (SpO₂; Masimo Radical-7 pulse
107 oximeter, Irvine, CA) and heart rate were monitored.

108 Lung function measurements were recorded during relaxed quiet sleep in supine
109 position using the Jaeger MasterScreen BabyBody device (v4.6; CareFusion, San
110 Diego, CA; Rendell-Baker Soucek facemask (size 0 or 1; Rüsck UK Ltd., High
111 Wycombe, UK), sealed with a rim of therapeutic putty. Measurements included tidal
112 breathing analysis, passive respiratory mechanics and functional residual capacity
113 (FRC_p). FRC_p was measured as described previously with the infant making respiratory
114 efforts against a closed shutter not using the raised volume technique⁸⁻⁹. Total
115 respiratory compliance (C_{rs}), was assessed in single occlusion technique (SOT) using
116 five to eight regular tidal breaths to establish a stable end-expiratory level (EEL) before
117 activating the balloon shutter. FRC_p, C_{rs} and tidal volume (TV) were normalized to body
118 weight (kg).

119 **ILFT analysis.** The following quality criteria were applied¹⁰: For C_{rs} and FRC_p a
120 minimum of five technically satisfactory measurements were obtained and the mean
121 of 3–5 valid measurements was calculated. The ‘within subject within-occasion
122 coefficient of variability (CV)’ was reported as [SD/mean] x 100.

123 **S4 Statistical analyses**

124 Missing values were imputed by sampling from a normal distribution with the sample
125 mean and standard deviation of the observed values for each variable, in which the

126 covariance structure was taken into account for the highly correlated MRI variables. A
127 logistic Group Lasso model ¹¹ with alpha optimization was used to identify MR imaging
128 and lung function variables best explaining the disease outcome. For all variables used
129 in the Grouped Lasso model a maximum of 19.6 percent missing values had to be
130 considered. The percentage of missing values was mainly impacted by the availability
131 of lung function data. Missing values of the imaging data were imputed considering the
132 covariance structure because of the highly correlated MRI variables. Missing values
133 for the lung function data was imputed by sampling from a normal distribution with the
134 sample mean and standard deviation of the observed values for each variable.

135 To model binary disease outcomes, BPD was dichotomized in two different ways: mild,
136 moderate and severe BPD vs. no BPD; moderate/severe BPD vs. no/mild BPD.

137 A Grouped Lasso Logistic model was used to estimate the impact of different variables
138 on the outcome BPD; independent variables included gestational age, gender, birth
139 weight, antenatal corticosteroids, early onset infection and imaging data. To account
140 for confounder effects, the clinical variables were included in the statistical model
141 reflecting the panel of known risk factors for disease development ^{12, 13-15}.

142 The Grouped Lasso Logistic model was repeated using lung function and imaging data
143 as independent variables. Quality of the models was assessed by leave-one-out cross
144 validation for unbiased validation avoiding overoptimistic AUC for model validation.

145 Model validation was realized in an independent study cohort calculating ROC and
146 AUC by comparing predicted results with true output.

147 Confirmation of the results was obtained using logistic regression (no vs.
148 mild/moderate/severe BPD) under consideration of the confounders GA, gender,
149 steroids and early infection. Testing for a potential difference in T2/T1 relaxation times
150 regarding the need for home monitoring was performed using a Two Sample t-test.

151 **S5 Results**

152 ***Quantification of structural changes in BPD lungs by advanced MRI***

153 40 preterm infants were included in the exploration cohort (mean age at imaging 35.4
154 weeks GA, n=21 female). 21 infants were included in the independent validation cohort
155 (mean age at imaging 37.7 weeks GA, n=14 female) (Table S1).

156 By regularized linear modelling, we identified quantitative MR imaging parameters
157 associated with the diagnosis of BPD in premature infants near term. As correlation
158 plot analysis of regional values, i.e. upper right, upper left, lower right, lower left lung,
159 for T1 and T2 relaxation times indicated their clustering, presentation of the results
160 refers to the entire group of T1 and T2 values, respectively.

161 Model coefficients for the logistic imaging model are summarized in Table 1 in the main
162 document. The estimates for the model parameter coefficients express the strength of
163 the imaging variables to identify the outcome variable BPD. To provide more
164 information about the precision of our estimates we performed a non-parametric
165 bootstrap procedure with B=100 replicates and calculated 95% percentile bootstrap
166 intervals (Figures S4, S6 and S7).

167 Furthermore, we included 95% confidence intervals for the coefficients of the imaging
168 and the clinical regression model (Figures S8 and S9).

169 Logistic regression analysis with the count variables 'days of oxygen' or 'days of
170 mechanical ventilation (MV)' (birth to discharge) confirmed the results obtained by
171 nominal variable analysis in the grouped Lasso Logistic model (Figures S2 and S3).

172 Comparison of T1 and T2 relaxation times between the exploration and the
173 confirmation cohort showed no statistical differences.

174 Infants with the need for home monitoring had significantly higher T2 relaxation times
175 compared to those discharged without home monitoring ($p=0.04$), indicating more

176 severe and persistent lung disease in infants with increased T2 relaxation times (Figure
177 S5).

178 Image analysis was done considering potential regional differences reflecting the
179 characteristic inhomogeneity of the disease. Total values represent results obtained
180 for the entire lung (Figure S1).

181 **Legend Figures S2-S4 and S6-S9**

182 beta coefficients: quantify the strength of the variables (clinical, imaging and lung
183 function) identifying the outcome variable BPD; steroids (yes)=antenatal steroids; T2
184 total=total value of T2 relaxation time; T1 total=total value of T1 relaxation time; T1
185 (upper right), T1 (lower right), T1 (upper left) and T1 (lower left): for mapping analysis
186 the lung was manually virtually segmented into four lung quadrants;
187 FRC_p_pre=functional residual capacity; CrsSO.kg_pre=compliance of total
188 respiratory system per kilogram (single occlusion); TV.kg=tidal volume per kilogram

189

190

191

192

193

194

195

196

197

198

199

200

201 REFERENCES

- 202 1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001;163(7):1723-9.
203 doi: 10.1164/ajrccm.163.7.2011060 [published Online First: 2001/06/13]
- 204 2. Franz AR, Steinbach G, Kron M, et al. Interleukin-8: a valuable tool to restrict antibiotic therapy in
205 newborn infants. *Acta Paediatr* 2001;90(9):1025-32. [published Online First: 2001/10/31]
- 206 3. Couchard M, Polge J, Bomsel F. [Hyaline membrane disease: diagnosis, radiologic surveillance,
207 treatment and complications]. *Ann Radiol (Paris)* 1974;17(7):669-83. [published Online First:
208 1974/11/01]
- 209 4. Sherman MP, Goetzman BW, Ahlfors CE, et al. Tracheal aspiration and its clinical correlates in the
210 diagnosis of congenital pneumonia. *Pediatrics* 1980;65(2):258-63. [published Online First:
211 1980/02/01]
- 212 5. Rosset A, Spadola L, Ratib O. OsiriX: an open-source software for navigating in multidimensional
213 DICOM images. *J Digit Imaging* 2004;17(3):205-16. doi: 10.1007/s10278-004-1014-6
214 [published Online First: 2004/11/10]
- 215 6. Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D Slicer as an image computing platform for the
216 Quantitative Imaging Network. *Magn Reson Imaging* 2012;30(9):1323-41. doi:
217 10.1016/j.mri.2012.05.001 S0730-725X(12)00181-6 [pii] [published Online First: 2012/07/10]
- 218 7. Bates JH, Schmalisch G, Filbrun D, et al. Tidal breath analysis for infant pulmonary function testing.
219 ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European
220 Respiratory Society/American Thoracic Society. *Eur Respir J* 2000;16(6):1180-92. [published
221 Online First: 2001/04/09]
- 222 8. Stocks J, Godfrey S, Beardsmore C, et al. Plethysmographic measurements of lung volume and airway
223 resistance. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European
224 Respiratory Society/ American Thoracic Society. *Eur Respir J* 2001;17(2):302-12. [published
225 Online First: 2001/05/04]
- 226 9. Hulskamp G, Pillow JJ, Dinger J, et al. Lung function tests in neonates and infants with chronic lung
227 disease of infancy: functional residual capacity. *Pediatr Pulmonol* 2006;41(1):1-22. doi:
228 10.1002/ppul.20318 [published Online First: 2005/12/07]
- 229 10. Nguyen TTD, Hoo AF, Lum S, et al. New Reference Equations to improve Interpretation of Infant
230 Lung Function. *Pediatr Pulmonol* 2012 doi: 10.1002/ppul.22656
- 231 11. Breheny P, Huang J. Group descent algorithms for nonconvex penalized linear and logistic
232 regression models with grouped predictors. *Stat Comput* 2015;25(2):173-87. doi:
233 10.1007/s11222-013-9424-2 [published Online First: 2015/03/10]
- 234 12. Bose CL, Dammann CE, Laughon MM. Bronchopulmonary dysplasia and inflammatory biomarkers
235 in the premature neonate. *Arch Dis Child Fetal Neonatal Ed* 2008;93:F455-F61.
- 236 13. Bhandari V. Hyperoxia-derived lung damage in preterm infants. *Semin Fetal Neonatal Med*
237 2010;15:223-29.
- 238 14. Gortner L, Misselwitz B, Milligan D, et al. Rates of bronchopulmonary dysplasia in very preterm
239 neonates in Europe: results from the MOSAIC cohort. *Neonatology* 2011;99:112-17.
- 240 15. Gortner L, Shen J, Tutdibi E. Sexual dimorphism of neonatal lung development. *Klin Padiatr*
241 2013;225:64-69.

242

243

244

245

246

247 **Table S1. Patient characteristics**

248		Exploration cohort	Confirmation cohort
249	n	40	21
250	Gestational age (weeks PMA)	27.7 (24.1-30.6)	25.6 (24.4-29.6)
251	Birth weight (g)	925 (415-1770)	810 (340-1470)
252	Gender (female/male)	21/19	14/7
253	pH, umbilical artery	7.34 (6.95-7.47)	7.34 (7.01-7.48)
254	Antenatal corticosteroids	36 (90%)	20 (95.2%)
255	Chorioamnionitis	19 (47.5%)	15 (71.4%)
256	Early onset infection	9 (22.5%)	4 (19%)
257	RDS \geq grade 3	11 (27.5%)	3 (14.3%)
258	Days of mechanical ventilation	36.5 (0-78)	24 (2-74)
259	- Endotracheal mechanical ventilation (n/days)	6 (0-34)	2 (0-32)
260	- Pharyngeal ventilation/CPAP (n/days)	33 (0-55)	18 (2-56)
261	PDA	20 (50.0%)	15 (71.4%)
262	Postnatal corticosteroids	18 (45.0%)	1 (4.8%)
263	ROP \geq grade 3	2 (5.0%)	6 (28.6%)
264	IVH \geq grade 3	1 (2.5%)	3 (14.3%)
265	ICU stay (days)	60 (30-127)	36 (5-93)
266	BPD		
267	- None	20 (50.0%)	4 (19%)
268	- Mild	12 (30.0%)	9 (42.9)
269	- Moderate	4 (10.0%)	2 (9.5%)
270	- Severe	4 (10.0%)	6 (28.6%)

271

272 Data are given as median and range or number and percent of total in group. PMA, post-
 273 menstrual age; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; CPAP,
 274 continuous positive airway pressure; ROP, retinopathy of prematurity; IVH, intraventricular
 275 haemorrhage; ICU, intensive care unit; BPD, Bronchopulmonary Dysplasia.

276